Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01403155 · ClinicalTrials.gov registry record · Phase 1
A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01403155 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT01403155, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
DNA vaccines consist of small pieces of DNA also known as plasmids, and have several potential advantages over traditional vaccines. Thus far, DNA vaccines appear to be well tolerated in humans. The investigators have developed a DNA vaccine, INO-3401, which includes plasmids targeting the proteins of the H5N1 avian influenza virus. The vaccine will be delivered via electroporation (EP) which uses the CELLECTRA constant current device to deliver a small electric charge following injection, since animal studies have shown that this delivery method increases the immune response to vaccine. The vaccine will be given to up 30 healthy adult subjects who have participated in study FLU-001. It is hypothesized that a booster dose with INO-3401 + EP will be well tolerated and immunogenic.
Interventions
- BIOLOGICAL INO-3401 + EP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01403155
The ClinicalTrials.gov registry entry for NCT01403155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INO-3401 + EP is the first listed.
NCT01403155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01403155 about?
NCT01403155 is a clinical study titled "A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001". DNA vaccines consist of small pieces of DNA also known as plasmids, and have several potential advantages over traditional vaccines. Thus far, DNA vaccines appear to be well tolerated in humans. The investigators have developed a DNA vaccine, INO-3401, which includes plasmids targeting the proteins ...
What is the current status of trial NCT01403155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01403155?
The interventions under investigation include: INO-3401 + EP (BIOLOGICAL).
Who is sponsoring clinical trial NCT01403155?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.